Helix Biopharma Corp.
HBPCF
$1.71
-$0.02-1.16%
OTC PK
| 01/31/2026 | 10/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -49.33% | 11.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.82% | -4.09% | |||
| Operating Income | 24.82% | 4.09% | |||
| Income Before Tax | 29.57% | -5.05% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 29.57% | -5.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 29.57% | -5.05% | |||
| EBIT | 24.82% | 4.09% | |||
| EBITDA | 24.76% | 4.21% | |||
| EPS Basic | 30.21% | 2.04% | |||
| Normalized Basic EPS | 30.00% | 1.64% | |||
| EPS Diluted | 30.21% | 2.04% | |||
| Normalized Diluted EPS | 30.00% | 1.64% | |||
| Average Basic Shares Outstanding | 0.67% | 7.02% | |||
| Average Diluted Shares Outstanding | 0.67% | 7.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||